Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
Bristol-Myers Squibb is not the subject of this release: it is a GlobeNewswire-distributed BioMedWire sponsored editorial profiling Quantum BioPharma's FDA clearance to run a Phase 2 trial of Lucid-MS, a first-in-class PAD2 inhibitor designed to protect and potentially rebuild myelin in multiple sclerosis. BMY appears only in the closing roundup of industry developments, which recaps previously released positive Phase 2 results for arlocabtagene autoleucel (arlo-cel) in quadruple-class exposed relapsed/refractory multiple myeloma from the QUINTESSENTIAL trial.
Key figures
- Drug Name
- Lucid-MS (Lucid-21-302)
- Phase Of Trial
- Phase 2
- Ms patients us
- roughly one million
- Tgtx trial size
- approximately 60 adults
- Ms patients global
- 2.9 million
- Ms market size 2030
- $38.62 billion
- Ind submission pages
- roughly 15,000 pages
- Pluvicto risk reduction
- 28%
- Qntm price target kingswood
- $45
- Qntm price target rodman renshaw
- $8
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.